Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Oncimmune Holdings Plc LSE:ONC London Ordinary Share GB00BYQ94H38 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  4.50 1.86% 246.50 243.00 250.00 246.50 236.00 246.50 34,753 08:00:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.5 -9.8 -13.4 - 170

Oncimmune Holdings PLC Notice of Half Year Results

25/01/2021 7:00am

UK Regulatory (RNS & others)


Oncimmune (LSE:ONC)
Historical Stock Chart


From Jan 2021 to Apr 2021

Click Here for more Oncimmune Charts.

TIDMONC

RNS Number : 6751M

Oncimmune Holdings PLC

25 January 2021

25 January 2021

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Notice of Half Year Results

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, will be announcing its half year results for the six months ended 30 November 2020 on Monday, 15 February 2021.

Adam Hill, Chief Executive Officer, together with Matthew Hall, Chief Financial Officer, will host a presentation and conference call for analysts at 11:30am GMT on the day of the results.

For conference call details please contact Alexander Davis of FTI Consulting at Alexander.Davis@fticonsulting.com or 020 3727 1000.

The management team will also host on Investor Meet Company a live presentation of the results on Monday, 15 February 2021 at 16:30 GMT.

-- The online presentation will be open to all existing shareholders and potential new investors.

-- Questions can be submitted before the event via your Investor Meet Company dashboard or at any time during the live presentation via the "Ask a Question" function. Responses to the Q&A will be published at the earliest opportunity on the Investor Meet Company platform.

-- Investor feedback can also be submitted directly to management immediately following the event.

Access to Investor Meet Company is free and interested parties can register to attend the presentation via the following link: https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor

Attendees who have already registered on the Investor Meet Company platform to meet the Company will automatically receive an invitation to the presentation.

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000

N+1 Singer (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer

+44 (0)20 7496 3000

WG Partners (Joint Broker)

David Wilson, Chris Lee

+44 (0)203 705 9321

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com

+44 (0)20 3727 1000

About Oncimmune

Our intimate understanding of the human immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies. The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and to give people extra time.

Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Oncimmune has a diversified and growing revenue from its portfolio of diagnostic products to detect early-stage cancer and a contract discovery and development service-based platform, delivering actionable insights into therapies to its pharmaceutical and biotech partners .

Oncimmune's ImmunoINSIGHTS platform enables life-science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to GBP3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a partner representative office in Shanghai, China.

For more information, visit www.oncimmune.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORDZGZMRZDGMZM

(END) Dow Jones Newswires

January 25, 2021 02:00 ET (07:00 GMT)

1 Year Oncimmune Chart

1 Year Oncimmune Chart

1 Month Oncimmune Chart

1 Month Oncimmune Chart
ADVFN Advertorial
Your Recent History
LSE
ONC
Oncimmune
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210414 13:00:07